Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this vehicle controlled study is to evaluate the efficacy and safety of
CD07805/47 gel 0.5% applied topically once daily (QD) for 4 weeks, and CD07805/47 gel 0.18%
applied topically once daily (QD) or twice daily (BID) for 4 weeks, in subjects with moderate
to severe facial erythema associated with rosacea.